← board
SHPH
Shuttle Pharmaceuticals, Inc.distress 10/10 · high distress / dilution risk$2.98-3%today-94% from 52w high
Oncology 1
Lead: glioblastoma
Revenue
pre-revenue
Liquidity
$3M
Runway
0.3 yrs
Shares 1y
+447%
Price & events
-87.4% over 6M
CatalystRating changeDilutionFinancingdashed = today
-2.6%
1D
-16.1%
1W
-22.4%
1M
-68.2%
3M
-88.1%
6M
-92.5%
1Y
-99.7%
2Y
—
5Y
-100.0%
All
Overview
- Market Cap
- $17.44M
- Volume
- 52.88K
- 52 Week Range
- $2.92 – $47.60
- Total Shares
- 5.85M
- Float Shares
- 582.38K
- Short %
- 23.76%
- % Held by Insiders
- 6.30%
- % Held by Institutions
- 5.77%
- RVOL
- 0.01x
- Beta
- 1.29
Pipeline stages · 1 programs
Ropidoxuridine
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 0 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2025-12-01 | Phase 2 | Ropidoxuridineorphan | Glioblastoma, IDH-wildtype | 30 | terminated |
Upcoming readouts & decisions · our signals
1 upcoming event has our read — the sell-the-news timing call plus an experimental clinical estimate. Go Pro to see them.
Catalyst news & presentations · 7
- over the next 18 to 24 monthsreadoutPhase 2Ropidoxuridine · Trial completion and data readout expected within 18-24 months from October 2024.SEC 8-K
- Wednesday, April 23, 2025 at 2:30 p.m. Pacific Timeconferencedata presentationsecondaryPhase 2Ropidoxuridine · Presentation at Planet MicroCap Showcase: VEGAS 2025 providing overview and update on Phase 2 trial of Ropidoxuridine and RT for glioblastoma.SEC 8-K
- 2025-03-12partnershipUnderwriting agreement with WestPark Capital for public offering.SEC 8-K
- Monday, January 13, 2025 at 3:30 p.m. ETconferencedata presentationsecondaryRopidoxuridine · CEO fireside chat at Lytham Partners 2025 Investor Healthcare Summit to discuss Phase 2 trial progressSEC 8-K
- 2024-12-16partnershipPSMA-B ligand · Sponsored research agreement with UCSF for preclinical development of PSMA-B as a theranostic.SEC 8-K
- Wednesday, October 30, 2024 at 8:30am ETconferencedata presentationsecondaryPhase 2Ropidoxuridine · CEO to present update on Phase 2 clinical trial of Ropidoxuridine for glioblastoma at ThinkEquity Conference.SEC 8-K
- October 29, 2024trial initiationsecondaryPhase 2Ropidoxuridine · First three patients dosed in Phase 2 trial of Ropidoxuridine for glioblastoma.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- no recent rating changes
Competitors — glioblastoma
- BNTXBioNTech SE$23.1B · D1
- IBRXImmunityBio, Inc.$7.8B · D5
- TNGXTango Therapeutics, Inc.$4.0B · D5
- BDTXBlack Diamond Therapeutics, Inc.$104M · D5
- NTHINEONC TECHNOLOGIES HOLDINGS, INC.$91M · D9
- MBIOMUSTANG BIO, INC.$15M · D5
- INABIN8BIO, INC.$12M · D7
- CNSPCNS Pharmaceuticals, Inc.$8M · D10
- CURXCuranex Pharmaceuticals Inc$6M · D8
Recent news
- 2026-07-21SHPH: Shuttle Pharmaceuticals Holdings Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
- 2026-07-21Shuttle Pharmaceuticals Company Profile & Introduction - Moomoo
- 2026-07-17HRT FINANCIAL LP Acquires Additional Shares in Shuttle Pharmaceu - GuruFocus
- 2026-07-16Shuttle Pharmaceuticals Holdings Inc (SHPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
- 2026-07-16HRT FINANCIAL LP Reduces Stake in Shuttle Pharmaceuticals Holdin - GuruFocus
- 2026-07-15Insider Sell: Financial Hrt Sells 83,149 Shares of Shuttle Pharm - GuruFocus
- 2026-07-15Insider Sell: Financial Hrt Sells 83,149 Shares of Shuttle Pharm - GuruFocus
- 2026-07-15Form 4 Shuttle Pharmaceuticals Inc For: 15 July By Investing.com - Investing.com Canada
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.